Arromax Pharmatech EP4 compound 36

Arromax Pharmatech EP4 compound 36: sourced facts only. name: "Herein, a novel series of indole-2-carboxamide derivatives were identified as selective EP4 antagonists, and SAR studies led to the discovery of the potent compound 36." [PMID:37312837]; target: "Herein, a novel series of indole-2-carboxamide derivatives were identified as selective EP4 antagonists, and SAR studies led to the discovery of the potent compound 36." [PMID:37312837]; developer: "Arromax Pharmatech Co. Ltd. Sangtiandao Innovation Park, No. 1 Huayun Road, SIP, Suzhou 215123, P. R. China." [PMID:37312837]; stage: "Compound 36 inhibited tumor growth in a CT-26 colon cancer xenograft better than E7046 and a combination of 36 with capecitabine significantly suppressed tumor growth (TGI up to 94.26%) in mouse models." [PMID:37312837]